| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 534.50M | 785.92M | 889.55M | 1.04B | 1.41B | 1.51B |
| Gross Profit | 387.50M | 533.10M | 529.30M | 622.40M | 786.68M | 866.41M |
| EBITDA | 1.17B | -194.89M | 74.73M | -244.95M | 333.00M | 433.05M |
| Net Income | 1.06B | -345.70M | -112.25M | -251.40M | 119.62M | 223.75M |
Balance Sheet | ||||||
| Total Assets | 968.75M | 550.28M | 982.03M | 1.03B | 1.50B | 1.41B |
| Cash, Cash Equivalents and Short-Term Investments | 170.15M | 53.02M | 109.37M | 178.33M | 182.74M | 236.97M |
| Total Debt | 3.45M | 1.48B | 1.49B | 1.51B | 1.74B | 1.75B |
| Total Liabilities | 645.76M | 1.66B | 1.74B | 1.71B | 2.18B | 2.22B |
| Stockholders Equity | 322.99M | -1.11B | -761.09M | -683.82M | -685.54M | -808.94M |
Cash Flow | ||||||
| Free Cash Flow | 40.00M | -17.56M | -29.61M | 38.39M | 134.40M | 248.78M |
| Operating Cash Flow | 29.59M | -16.84M | 6.69M | 76.65M | 182.38M | 295.59M |
| Investing Cash Flow | -11.59M | -16.41M | -74.70M | -42.64M | -52.62M | -63.96M |
| Financing Cash Flow | 154.73M | -17.34M | -2.75M | -4.72M | -182.99M | -74.35M |
WW International, Inc. is currently recruiting participants for a study titled ‘The Comparative Effectiveness of Commercial Weight Management Programs in Adults Living With Overweight or Obesity: A Randomized Controlled Trial.’ The study aims to evaluate the effectiveness of three commercial weight management programs by measuring absolute and percentage weight change over 12 weeks. This research is significant as it seeks to provide evidence-based insights into the efficacy of popular weight management solutions.
WeightWatchers’ recent earnings call presented a mixed sentiment, highlighting both significant achievements and ongoing challenges. The company has made notable progress in debt reduction and strategic reorganization, evidenced by its relisting on NASDAQ and an increase in average revenue per user (ARPU). However, these positive developments are tempered by difficulties in subscriber retention, a decline in revenue, and negative media coverage stemming from bankruptcy. Additionally, the transition from compounded semaglutide poses short-term obstacles.